

Special Issue

West Nile Virus Disease

Message from the Guest Editors

West Nile virus (WNV) is the most common mosquito-borne virus in North America. WNV can enter the central nervous system (CNS) and cause WN neuroinvasive disease (WNND) with less understood long term consequences. An association between the WN infection and myasthenia gravis was recently observed in patients long after they recovered from WNND and no prior history of myasthenia gravis. The exact reason for the long-term lingering symptoms after WNV infection are still not well characterized. Therefore, we would like to encourage submission of articles to this special issue, which will cover recent advances in understanding the mechanisms of WNV invasion/infection and neurodegeneration in the CNS, the cause of WNND and reasons for lingering neurological symptoms. Identification of novel therapeutic drugs/peptides, which can suppress the pathologic phenotype is important, articles on this topic are also welcome.

Guest Editors

Dr. Parminder J.S. Vig

Neurology Research Division, Professor of Neurology and Biochemistry,
Department of Neurology, University of Mississippi Medical Center,
2500 North State Street, Jackson, MS 39216, USA

Prof. Dr. Fengwei Bai

Cell and Molecular Biology Program, University of Southern Mississippi,
Hattiesburg, MS 39406, USA

Deadline for manuscript submissions

closed (31 December 2020)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/37189

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).